TOKYO, Aug 2 (Reuters) - Japan’s Astellas Pharma (4503.T) on Monday reported an 18.2 percent drop in first-quarter recurring profit amid intensified competition, and slashed its annual outlook as it booked a licence extension fee and as a stronger yen took its toll.
